What is HC Wainwright’s Forecast for DNLI FY2027 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for Denali Therapeutics in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $1.68 for the year, down from their previous forecast of $1.69. HC Wainwright has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.53) per share.

DNLI has been the subject of several other reports. Jefferies Financial Group upped their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their target price on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Citigroup lifted their target price on Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Bank of America increased their price target on Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, Wedbush cut their target price on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $38.90.

Denali Therapeutics Stock Up 5.9 %

Shares of NASDAQ:DNLI opened at $31.35 on Friday. The company has a market capitalization of $4.49 billion, a price-to-earnings ratio of -11.00 and a beta of 1.40. The company has a 50 day moving average of $27.81 and a two-hundred day moving average of $23.51. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $32.13.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the firm posted ($0.72) earnings per share.

Insiders Place Their Bets

In other news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the transaction, the director now directly owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Denali Therapeutics news, CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now directly owns 235,807 shares of the company’s stock, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now directly owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is owned by corporate insiders.

Institutional Trading of Denali Therapeutics

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Denali Therapeutics in the first quarter valued at approximately $147,000. ClariVest Asset Management LLC grew its holdings in Denali Therapeutics by 18.8% in the 1st quarter. ClariVest Asset Management LLC now owns 47,748 shares of the company’s stock worth $980,000 after buying an additional 7,568 shares in the last quarter. Swiss National Bank increased its position in Denali Therapeutics by 0.7% in the 1st quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after acquiring an additional 1,500 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in Denali Therapeutics during the 1st quarter valued at $4,330,000. Finally, Headlands Technologies LLC bought a new stake in Denali Therapeutics during the 1st quarter valued at $88,000. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.